Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
| ▸ | FASN | P49327 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875887 | 1.00 | CTRB1 (0.41) | CTRB1MC4RF2PRSS1CYP19A1 | |
| SCHEMBL20875888 | 1.00 | CTRB1 (0.41) | CTRB1MC4RF2PRSS1CYP19A1 | |
| SCHEMBL20875936 | 0.88 | CTRB1 (0.39) | CTRB1MC4RF2PRSS1CYP19A1 | |
| SCHEMBL20875907 | 0.86 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL20875905 | 0.86 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL22279740 | 0.84 | NAAA (0.41) | MC4RNAAATSHRHSD17B10 | |
| SCHEMBL20875895 | 0.84 | NAAA (0.41) | MC4RNAAATSHRHSD17B10 | |
| SCHEMBL22279878 | 0.82 | PKM (0.46) | NAAATSHR | |
| SCHEMBL22279804 | 0.82 | PKM (0.46) | NAAATSHR | |
| SCHEMBL20875984 | 0.81 | NAAA (0.43) | NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-11-23 | — | — | US | disclosed |
| EP-3692035-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2020-08-12 | — | — | EP | disclosed |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2020-07-30 | — | — | US | disclosed |
| WO-2019068841-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2019-04-11 | — | — | WO | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | PLA2G1B, PLA2G4A, PLA2G4C | CTRB1 663/4885MC4R 3452/4885F2 1693/4885 |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G4A, PLA2G4C | CTRB1 663/4885MC4R 3452/4885F2 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.